Eli Lilly and Company
LLY
$1,189.41
-$44.25-3.59%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 49.58% | 47.44% | 44.71% | 45.41% | 36.83% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 49.58% | 47.44% | 44.71% | 45.41% | 36.83% |
| Cost of Revenue | 43.01% | 38.30% | 31.30% | 29.25% | 23.43% |
| Gross Profit | 50.96% | 49.48% | 47.79% | 49.23% | 40.03% |
| SG&A Expenses | 24.78% | 27.59% | 31.55% | 39.11% | 35.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.69% | 30.25% | 27.47% | 28.10% | 24.03% |
| Operating Income | 77.39% | 73.21% | 73.03% | 75.60% | 59.91% |
| Income Before Tax | 99.27% | 128.87% | 102.93% | 121.70% | 87.55% |
| Income Tax Expenses | 125.01% | 134.52% | 143.61% | 129.78% | 85.76% |
| Earnings from Continuing Operations | 93.56% | 127.60% | 94.90% | 119.98% | 87.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 93.56% | 127.60% | 94.90% | 119.98% | 87.96% |
| EBIT | 77.39% | 73.21% | 73.03% | 75.60% | 59.91% |
| EBITDA | 72.17% | 67.96% | 67.39% | 69.35% | 55.48% |
| EPS Basic | 94.56% | 128.75% | 95.78% | 120.65% | 88.34% |
| Normalized Basic EPS | 81.37% | 76.10% | 73.70% | 79.84% | 63.35% |
| EPS Diluted | 94.75% | 129.01% | 95.96% | 121.03% | 88.57% |
| Normalized Diluted EPS | 81.50% | 76.27% | 73.90% | 80.09% | 63.31% |
| Average Basic Shares Outstanding | -0.53% | -0.46% | -0.40% | -0.28% | -0.13% |
| Average Diluted Shares Outstanding | -0.61% | -0.57% | -0.52% | -0.40% | -0.09% |
| Dividend Per Share | 15.36% | 15.37% | 15.38% | 15.31% | 15.23% |
| Payout Ratio | -0.41% | -0.49% | -0.41% | -0.48% | -0.39% |